OTCMKTS:NPHC Nutra Pharma (NPHC) Stock Price, News & Analysis $0.0001 0.00 (-75.00%) As of 06/12/2026 01:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Nutra Pharma Stock (OTCMKTS:NPHC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nutra Pharma alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000550-Day Range N/A52-Week Range$0.0001▼$0.0050Volume1.97 million shsAverage Volume2.11 million shsMarket Capitalization$715.97 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Nutra Pharma Corporation is a development-stage medical technology company focusing on the research and development of therapeutic products for gastrointestinal disorders, notably those arising from opioid use. The company is advancing a portfolio of proprietary formulations designed to address opioid-induced constipation (OIC), a common side effect of pain management regimens. Its lead candidate, RIMSO-50, is an oral solution being evaluated for its potential to alleviate OIC by promoting bowel movements without compromising the effectiveness of opioid analgesics. Nutra Pharma is leveraging its in-house formulation capabilities and preclinical data to support ongoing regulatory submissions and potential partner collaborations. Nutra Pharma holds patent protection in key jurisdictions, including the United States, Europe and Israel, covering its novel formulations and methods of use. The company’s intellectual property strategy is aimed at securing market exclusivity and facilitating potential licensing agreements. Headquartered in Tel Aviv, Israel, Nutra Pharma is building its operational footprint with activities in North America and Europe. While the company remains in the clinical and regulatory phase, it seeks to advance its product pipeline through strategic partnerships and capital investment to bring its therapies to patients in need.AI Generated. May Contain Errors. Read More Receive NPHC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nutra Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NPHC Stock News HeadlinesNutra Pharma Corp (NPHC)April 9, 2025 | uk.investing.comPharmaNutra SpA: Strong Sales Growth and International Expansion Reinforce Buy RatingSeptember 11, 2024 | markets.businessinsider.comSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $1.75 trillion valuation and 266 times earnings, you're buying in at the most expensive IPO in history - right when institutions who got in at $800 billion need someone to sell to. Dylan Jovine has identified a small company in Musk's supply chain that builds the power infrastructure Colossus can't run without - and it's still trading at a fraction of its value.June 14 at 1:00 AM | Behind the Markets (Ad)Biscuit brand Britannia forays into healthtech with NutriPlus appApril 3, 2024 | msn.comNutra Pharma Corp. Reaches Settlement with SECMarch 22, 2024 | globenewswire.comCollegium PharmaceuticalMarch 3, 2024 | forbes.comNutra Pharma Corp.February 21, 2024 | wsj.comNutri Pharmaceuticals Research Inc.October 7, 2023 | barrons.comSee More Headlines NPHC Stock Analysis - Frequently Asked Questions How have NPHC shares performed this year? Nutra Pharma's stock was trading at $0.0001 at the beginning of the year. Since then, NPHC shares have increased by 0.0% and is now trading at $0.0001. How were Nutra Pharma's earnings last quarter? Nutra Pharma Corp. (OTCMKTS:NPHC) announced its quarterly earnings data on Friday, August, 17th. The company reported $0.00 EPS for the quarter. The business had revenue of $0.03 million for the quarter. How do I buy shares of Nutra Pharma? Shares of NPHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nutra Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nutra Pharma investors own include Jumia Technologies (JMIA), Prospect Capital (PSEC), Tilray Brands (TLRY), AGNC Investment (AGNC) and Aktis Oncology (AKTS). Company Calendar Last Earnings8/17/2018Today6/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:NPHC CIK1119643 Webwww.nutrapharma.com Phone(954) 509-0911Fax877-895-5647Employees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.05 million Net Margins-364.90% Pretax Margin-364.90% Return on EquityN/A Return on Assets-159.08% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.03 Sales & Book Value Annual Sales$380 thousand Price / Sales1.88 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares7,159,740,000Free Float2,756,500,000Market Cap$715.97 thousand OptionableNot Optionable Beta1.02 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:NPHC) was last updated on 6/14/2026 by MarketBeat.com Staff. From Our PartnersThis Could Be the Biggest Monetary Shift in 50 YearsTucked inside U.S. Code Title 31, Section 5117 is a provision allowing the Treasury to reprice America's gold ...Americas Gold Company | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredForbes calls this a "golden era" for retirement incomeForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredThe S-1 disclosure Wall Street is racing to traceWhen SpaceX filed its S-1, the SEC required full disclosure of costs - and power consumption for 1 million GPU...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nutra Pharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nutra Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.